YF-2 NEW
| Price | $50 | $122 | $197 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: YF-2 | CAS No.: 1311423-89-8 |
| Purity: 99.33% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | YF-2 |
| Description | YF-2 is blood-brain-barrier permeable histone acetyltransferase activator, acetylates H3 in the hippocampus, CBP, PCAF, and GCN5 with EC50s of 2.75 μM, 29.04 μM and 49.31 μM , respectively |
| In vitro | YF-2 (0.03, 0.1, 0.25, 0.5, 1, 2.5, 5, 15, 40 and 80 μM, 72 hours) inhibits the preliferation of U251, CCRF-CEM, Hs578T, NCI-ADR-RES cells, respectively. |
| In vivo | YF-2, administered intraperitoneally at doses of 20 mg/kg (2 hours before an electric shock) or 5 mg/kg (30 minutes prior to the electric shock), effectively rescues the defect in contextual memory in mice. At a dosage of 20 mg/kg without the electric shock treatment, YF-2 exhibits no impact on contextual memory in mice. |
| Storage | Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Saline : 10 mg/mL (23.21 mM), Suspension. H2O : Insoluble DMSO : 245 mg/mL (568.64 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (9.28 mM), Sonication is recommended. |
| Keywords | YF-2 | YF2 | YF 2 | PCAF | Inhibitor | inhibit | HistoneAcetyltransferase | Histone Acetyltransferase | HATs | HAT | GCN5 | EpigeneticReaderDomain | Epigenetic Reader Domain | CBP |
| Inhibitors Related | ABBV-744 | SNDX-5613 | 3-methyl-1,2,3,4-tetrahydroquinazolin-2-one | (+)-JQ-1 | Acetaminophen | 5-Ph-IAA | Manganese chloride (tetrahydrate) | Curcumin | N4-Acetylcytidine | Naphthol AS-E | JQ-1 (carboxylic acid) | Bisdemethoxycurcumin |
| Related Compound Libraries | Histone Modification Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Epigenetics Compound Library | CNS-Penetrant Compound Library | Stem Cell Differentiation Compound Library | Anti-Cardiovascular Disease Compound Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Active Compound Library | Anti-Hypertension Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:1454920-20-7
-
-
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2500.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-04-21 | |
|
VIP2Y
|
Shenzhen Nexcon Pharmatechs Ltd.
|
2026-06-18 | ||
|
VIP3Y
|
Shandong Hanjiang Chemical Co., Ltd
|
2026-06-06 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY